Evidence map›Paper›PMID 22867128›Full record

ArticleLipids in health and disease2012

Antihyperglycemic and hypolipidemic effects of α, β-amyrin, a triterpenoid mixture from Protium heptaphyllum in mice.

Flávia Almeida Santos, Julyanne Torres Frota, Bruno Rodrigues Arruda, Tiago Sousa de Melo, Armenio André de Carvalho Almeida da Silva, Gerly Anne de Castro Brito, Mariana Helena Chaves, Vietla Satyanarayana Rao

Open access · goldAbstract read
In one paragraph

Article in Lipids in health and disease, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 1 synthesis or guideline pooled it, 176 citations in OpenAlex.

  1. A Systematic Review ofMolecules (Basel, Switzerland) · 2022
    Pooled it
  2. Antidiabetic Potential ofPlants (Basel, Switzerland) · 2025
    Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Effect of LiposomalBiology · 2024
    Article
  8. Article
  9. Article
  10. Alpha Amyrin Nano-Emulsion Formulation from Stem Bark ofTurkish journal of pharmaceutical sciences · 2024
    Article
  11. Cuticular Waxes and Cutin inMolecules (Basel, Switzerland) · 2023
    Article
  12. Triterpenoids fromACS omega · 2023
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. A review of alpha-glucosidase inhibitors from plants as potential candidates for the treatment of type-2 diabetes.Phytochemistry reviews : proceedings of the Phytochemical Society of Europe · 2022
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Flávia Almeida SantosDepartment of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará, Fortaleza, Ceará, Brazil. flavia@ufc.br
Julyanne Torres Frota
Bruno Rodrigues Arruda
Tiago Sousa de Melo
Armenio André de Carvalho Almeida da Silva
Gerly Anne de Castro Brito
Mariana Helena Chaves
Vietla Satyanarayana Rao
Universidade Federal do Ceará · BRUniversidade Federal do Piauí · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPentacyclic triterpenes in general exert beneficial effects in metabolic disorders. This study investigated the effects of α, β-amyrin, a pentacyclic triterpene mixture from the resin of Protium heptaphyllum on blood sugar level and lipid profile in normal and streptozotocin (STZ)-induced diabetic mice, and in mice fed on a high-fat diet (HFD).

findingsMice treated with α, β-amyrin (10, 30 and 100 mg/kg, p.o.) or glibenclamide (10 mg/kg, p.o.) had significantly reduced STZ-induced increases in blood glucose (BG), total cholesterol (TC) and serum triglycerides (TGs). Unlike glibenclamide that showed significant reductions in BG, TC and TGs in normoglycemic mice, α, β-amyrin did not lower normal blood sugar levels but at 100 mg/kg, manifested a hypolipidemic effect. Also, α, β-amyrin effectively reduced the elevated plasma glucose levels during the oral glucose tolerance test. Moreover, the plasma insulin level and histopathological analysis of pancreas revealed the beneficial effect of α, β-amyrin in the preservation of beta cell integrity. In mice treated orally with α, β-amyrin (10, 30 and 100 mg/kg) or fenofibrate (200 mg/kg), the HFD-associated rise in serum TC and TGs were significantly less. The hypocholesterolemic effect of α, β-amyrin appeared more prominent at 100 mg/kg with significant decreases in VLDL and LDL cholesterol and an elevation of HDL cholesterol. Besides, the atherogenic index was significantly reduced by α, β-amyrin.

conclusionsThese findings reflect the potential antihyperglycemic and hypolipidemic effects of α, β-amyrin mixture and suggest that it could be a lead compound for drug development effective in diabetes and atherosclerosis.

Indexed as

AnimalsBlood GlucoseCholesterolDiabetes Mellitus, ExperimentalDiet, High-FatDrug DiscoveryFenofibrateGlyburideHypercholesterolemiaHypoglycemic AgentsHypolipidemic AgentsInsulin-Secreting CellsMagnoliopsidaMaleMiceOleanolic Acidbeta-amyrinBlood GlucoseCholesterolFenofibrateGlyburideHypoglycemic AgentsHypolipidemic AgentsOleanolic AcidTriglycerides

Identifiers

PMID22867128
PMCPMC3484111
OpenAlexW2033781860

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.